Ubiquigent

Curated by Signal

Developer of novel deubiquitinase modulators as new therapeutics

Overview

Developer of novel deubiquitinase modulators as new therapeutics. The company has pipeline of drug discovery programmes and is developing a portfolio encompassing DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras and DUB-Targeting Chimeras for partnering and commercialisation.

Key facts

Founded: 2009
Headquarters: Dundee, United Kingdom
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

2 products and services: Sign up to view

Contact

Primary office: Sign up to view
Email: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Cyclic Diagnostics
Developer of point-of-care test solutions for fertility care
Life Sciences TechnologyCambridge, United Kingdom
TheraVR
Provider of non-drug interventions for pain with their wearable headset technology
Life Sciences TechnologyLondon, United Kingdom
PostEra
AI based molecular designing software for drug discovery
Life Sciences TechnologyLondon, United Kingdom

About Ubiquigent

What does Ubiquigent do?

Developer of novel deubiquitinase modulators as new therapeutics.

Where is Ubiquigent headquartered?

Ubiquigent is headquartered in Dundee, United Kingdom.

When was Ubiquigent founded?

Ubiquigent was founded in 2009.

Which sector is Ubiquigent in?

Ubiquigent operates in Life Sciences Technology.

Who are Ubiquigent's competitors?

Companies similar to Ubiquigent include Cyclic Diagnostics, TheraVR, and PostEra.